

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gladwin *et al.*

Application No. 10/563,683

Filed: October 4, 2006

Confirmation No. 3225

For: USE OF NITRITE SALTS FOR THE
TREATMENT OF CARDIOVASCULAR
CONDITIONS

FILED VIA EFS

Examiner: Anna Pagonakis

Art Unit: 1614

Attorney Reference No. 4239-67618-07

FILED VIA ELECTRONIC FILING SYSTEM
COMMISSIONER FOR PATENTS

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(4)

Listed on the accompanying form PTO-1449 are four English-language documents, three of which are submitted herewith. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement (IDS) before the mailing of a first Office action after the filing of a request for continued examination. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. § 1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301
cc: Docketing

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630